Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies

NCT02404441 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02404441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02404441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
April 27, 2015
Completion date
July 21, 2020
Enrollment
319 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer, melanoma, non-small sell lung cancer (nsclc), other solid tumors, triple negative breast cancer